IWP's Underlying Holdings Could Mean 11% Gain Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2025
0mins
Should l Buy VEEV?
Source: NASDAQ.COM
ETF Analysis: The iShares Russell Mid-Cap Growth ETF (IWP) has an implied analyst target price of $144.41, indicating a potential upside of 10.59% from its recent trading price of $130.58.
Stock Performance Insights: Notable underlying holdings such as Ionis Pharmaceuticals, Veeva Systems, and Ares Management show significant upside potential based on analyst targets, raising questions about the validity of these projections amidst market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VEEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VEEV
Wall Street analysts forecast VEEV stock price to rise
23 Analyst Rating
16 Buy
6 Hold
1 Sell
Moderate Buy
Current: 179.110
Low
222.00
Averages
317.10
High
380.00
Current: 179.110
Low
222.00
Averages
317.10
High
380.00
About VEEV
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data and business consulting and is designed to meet the needs of its customers and strategic business functions from research and development (R&D) through commercialization. Its product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes and partners across content management, training, quality management, assurance and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. It owns Ostro, a brand engagement platform for life sciences that gives an artificial intelligence (AI)-driven chat experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veeva Systems' Market Prospects and Challenges
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing significant competition, the demand for its cloud solutions in the life sciences sector is expected to continue growing, particularly with the aging global population and increasing consumer spending.
- Customer Base Advantage: Veeva's clientele includes 15 of the top 20 biopharma companies, and the high switching costs associated with its services enhance its competitive edge and market position, as clients rely heavily on its platform for critical operations.
- Market Opportunity Assessment: Veeva Systems estimates its current total addressable market at approximately $20 billion, and while revenue growth has slowed, the company still sees ample opportunities for strong revenue and profit growth over the next five years, especially within the life sciences sector.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an annual compound growth rate of 11.82%, which is slightly lower than its past performance but remains attractive given its market leadership and competitive advantages.
See More
Veeva Systems Faces Competitive Challenges Amid Strong Growth
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing competitive pressures, the demand in the life sciences sector is expected to grow, benefiting from an aging population and increased consumer spending.
- Strong Customer Base: Veeva serves 15 of the top 20 biopharma companies, and its clients' reliance on its services for critical activities like clinical trial data management and compliance provides a robust competitive edge.
- Broad Market Opportunities: With a current total addressable market of approximately $20 billion, Veeva Systems has the potential for strong revenue and profit growth over the next five years, especially as it expands into new markets like cosmetics and consumer packaged goods.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an 11.82% compound annual growth rate, which, while slightly lower than its historical performance, remains competitive in the current market landscape.
See More
Veeva Systems: Analyzing Future Growth Potential
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing competitive pressures, the demand in the life sciences sector is expected to continue growing, particularly with the aging population and increasing consumer spending.
- Customer Base Advantage: Veeva serves 15 of the top 20 biopharma companies, and the high switching costs for clients relying on its services enhance its market position and competitive edge in the industry.
- Market Opportunity Assessment: Veeva Systems estimates its current total addressable market at approximately $20 billion, and while revenue growth has slowed, the company still has opportunities for strong revenue and profit growth over the next five years, especially as it expands into new markets.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an 11.82% compound annual growth rate, which, while slightly lower than its past performance, positions it as a potential long-term investment given its leadership in core markets and competitive advantages.
See More
Veeva Systems' Strong Q4 Results Attract Analyst Attention
- Strong Earnings: Veeva Systems Inc. (NYSE:VEEV) reported fourth-quarter results in 2026 that exceeded market expectations, leading Truist to lower its price target from $275 to $262 while maintaining a Buy rating, indicating ongoing commercial momentum.
- Cautious Outlook: Truist highlighted that Veeva's guidance surpassed consensus estimates, reflecting customer planning cycles rather than expectations for macroeconomic improvements, showcasing the company's relatively cautious approach to guidance.
- Competitive Advantage: TD Cowen updated its model on the same day, reducing Veeva's price target from $380 to $300 but keeping a Buy rating, emphasizing that the integrated nature of Veeva's platform provides a significant competitive edge and alleviates concerns regarding AI-related risks.
- Positive Analyst Sentiment: As of March 6, 2026, over 70% of analysts maintain a bullish outlook on Veeva, with a consensus price target of $195.49, implying approximately 40.67% upside potential, despite the stock having fallen over 28% in the past six months.
See More
AOP Health Standardizes on Veeva Vault Platform to Accelerate Global Growth
- Platform Integration: AOP Health standardizes on the Veeva Vault platform, integrating clinical research, development, quality, and commercialization to enhance global operational efficiency and reduce time to patient access.
- Collaboration Efficiency: The new platform fosters collaboration among clinical, regulatory, safety, and quality teams, enabling more efficient development of new therapies while improving drug safety and compliance.
- Clear Market Positioning: AOP Health focuses on providing integrated therapy solutions for rare diseases and critical care, leveraging nearly 30 years of industry experience to address unmet medical needs and strengthen market competitiveness.
- Deepening Strategic Partnership: The collaboration between Veeva and AOP Health is founded on shared values, aiming to transform the service model for rare diseases and critical care through the Veeva Industry Cloud for Life Sciences, driving industry innovation.
See More
Veeva Acquires Ostro to Expand AI Engagement Tools
- Strategic Expansion: Veeva's acquisition of Ostro for approximately $100 million aims to enhance its AI tools, improving interactions between pharmaceutical brands and healthcare professionals, thereby boosting market competitiveness.
- Technology Integration: Ostro's AI-powered platform allows users to ask health-related questions through a conversational interface, providing verified information instantly, addressing the growing demand for compliant AI communication tools.
- Data Analysis Capability: The platform not only delivers approved answers and relevant educational materials but also collects engagement data, enabling brands to analyze user behavior and refine digital outreach strategies for improved communication efficiency.
- Industry Outlook: Veeva CEO Peter Gassner emphasized that AI is reshaping how consumers access health information, and Ostro's technology will ensure patients and doctors have instant access to accurate information, driving future customer engagement models.
See More
Veeva Systems' Market Prospects and Challenges
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing significant competition, the demand for its cloud solutions in the life sciences sector is expected to continue growing, particularly with the aging global population and increasing consumer spending.
- Customer Base Advantage: Veeva's clientele includes 15 of the top 20 biopharma companies, and the high switching costs associated with its services enhance its competitive edge and market position, as clients rely heavily on its platform for critical operations.
- Market Opportunity Assessment: Veeva Systems estimates its current total addressable market at approximately $20 billion, and while revenue growth has slowed, the company still sees ample opportunities for strong revenue and profit growth over the next five years, especially within the life sciences sector.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an annual compound growth rate of 11.82%, which is slightly lower than its past performance but remains attractive given its market leadership and competitive advantages.
See More
Veeva Systems Faces Competitive Challenges Amid Strong Growth
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing competitive pressures, the demand in the life sciences sector is expected to grow, benefiting from an aging population and increased consumer spending.
- Strong Customer Base: Veeva serves 15 of the top 20 biopharma companies, and its clients' reliance on its services for critical activities like clinical trial data management and compliance provides a robust competitive edge.
- Broad Market Opportunities: With a current total addressable market of approximately $20 billion, Veeva Systems has the potential for strong revenue and profit growth over the next five years, especially as it expands into new markets like cosmetics and consumer packaged goods.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an 11.82% compound annual growth rate, which, while slightly lower than its historical performance, remains competitive in the current market landscape.
See More
Veeva Systems: Analyzing Future Growth Potential
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing competitive pressures, the demand in the life sciences sector is expected to continue growing, particularly with the aging population and increasing consumer spending.
- Customer Base Advantage: Veeva serves 15 of the top 20 biopharma companies, and the high switching costs for clients relying on its services enhance its market position and competitive edge in the industry.
- Market Opportunity Assessment: Veeva Systems estimates its current total addressable market at approximately $20 billion, and while revenue growth has slowed, the company still has opportunities for strong revenue and profit growth over the next five years, especially as it expands into new markets.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an 11.82% compound annual growth rate, which, while slightly lower than its past performance, positions it as a potential long-term investment given its leadership in core markets and competitive advantages.
See More
Veeva Systems' Strong Q4 Results Attract Analyst Attention
- Strong Earnings: Veeva Systems Inc. (NYSE:VEEV) reported fourth-quarter results in 2026 that exceeded market expectations, leading Truist to lower its price target from $275 to $262 while maintaining a Buy rating, indicating ongoing commercial momentum.
- Cautious Outlook: Truist highlighted that Veeva's guidance surpassed consensus estimates, reflecting customer planning cycles rather than expectations for macroeconomic improvements, showcasing the company's relatively cautious approach to guidance.
- Competitive Advantage: TD Cowen updated its model on the same day, reducing Veeva's price target from $380 to $300 but keeping a Buy rating, emphasizing that the integrated nature of Veeva's platform provides a significant competitive edge and alleviates concerns regarding AI-related risks.
- Positive Analyst Sentiment: As of March 6, 2026, over 70% of analysts maintain a bullish outlook on Veeva, with a consensus price target of $195.49, implying approximately 40.67% upside potential, despite the stock having fallen over 28% in the past six months.
See More
AOP Health Standardizes on Veeva Vault Platform to Accelerate Global Growth
- Platform Integration: AOP Health standardizes on the Veeva Vault platform, integrating clinical research, development, quality, and commercialization to enhance global operational efficiency and reduce time to patient access.
- Collaboration Efficiency: The new platform fosters collaboration among clinical, regulatory, safety, and quality teams, enabling more efficient development of new therapies while improving drug safety and compliance.
- Clear Market Positioning: AOP Health focuses on providing integrated therapy solutions for rare diseases and critical care, leveraging nearly 30 years of industry experience to address unmet medical needs and strengthen market competitiveness.
- Deepening Strategic Partnership: The collaboration between Veeva and AOP Health is founded on shared values, aiming to transform the service model for rare diseases and critical care through the Veeva Industry Cloud for Life Sciences, driving industry innovation.
See More
Veeva Acquires Ostro to Expand AI Engagement Tools
- Strategic Expansion: Veeva's acquisition of Ostro for approximately $100 million aims to enhance its AI tools, improving interactions between pharmaceutical brands and healthcare professionals, thereby boosting market competitiveness.
- Technology Integration: Ostro's AI-powered platform allows users to ask health-related questions through a conversational interface, providing verified information instantly, addressing the growing demand for compliant AI communication tools.
- Data Analysis Capability: The platform not only delivers approved answers and relevant educational materials but also collects engagement data, enabling brands to analyze user behavior and refine digital outreach strategies for improved communication efficiency.
- Industry Outlook: Veeva CEO Peter Gassner emphasized that AI is reshaping how consumers access health information, and Ostro's technology will ensure patients and doctors have instant access to accurate information, driving future customer engagement models.
See More
